Versor Investments LP Acquires Shares of 14,300 Amneal Pharmaceuticals, Inc. $AMRX

Versor Investments LP acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 14,300 shares of the company’s stock, valued at approximately $120,000.

Other large investors have also added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in Amneal Pharmaceuticals by 5,975.0% during the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company’s stock valued at $26,000 after buying an additional 3,107 shares during the last quarter. Headlands Technologies LLC purchased a new position in Amneal Pharmaceuticals during the first quarter valued at $31,000. Amalgamated Bank raised its stake in Amneal Pharmaceuticals by 33.0% during the first quarter. Amalgamated Bank now owns 5,511 shares of the company’s stock valued at $46,000 after buying an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Amneal Pharmaceuticals during the fourth quarter valued at $52,000. Finally, Xponance Inc. raised its stake in Amneal Pharmaceuticals by 16.1% during the first quarter. Xponance Inc. now owns 13,183 shares of the company’s stock valued at $110,000 after buying an additional 1,828 shares during the last quarter. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

AMRX has been the subject of several recent analyst reports. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a “buy” rating and a $12.00 price target for the company. Wall Street Zen cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $11.60.

Amneal Pharmaceuticals Stock Performance

Amneal Pharmaceuticals stock opened at $9.59 on Friday. The stock has a market cap of $3.01 billion, a PE ratio of 959.96 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a one year low of $6.68 and a one year high of $9.79. The stock has a fifty day moving average of $8.38 and a 200 day moving average of $8.01.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, beating analysts’ consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, sell-side analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Insider Activity at Amneal Pharmaceuticals

In related news, EVP Andrew S. Boyer sold 279,244 shares of the company’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the completion of the sale, the executive vice president owned 152,426 shares in the company, valued at approximately $1,429,755.88. This represents a 64.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nikita Shah sold 71,694 shares of the company’s stock in a transaction on Thursday, August 14th. The shares were sold at an average price of $9.29, for a total value of $666,037.26. Following the sale, the executive vice president owned 267,235 shares of the company’s stock, valued at approximately $2,482,613.15. This trade represents a 21.15% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 456,374 shares of company stock worth $4,239,042. 26.56% of the stock is owned by insiders.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.